Huppertz Berthold, Kawaguchi Rie
Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria.
Wien Med Wochenschr. 2012 May;162(9-10):191-5. doi: 10.1007/s10354-012-0072-5.
A variety of different biomarkers to predict preeclampsia have been identified in the last ten years. Most of these markers have been detected and quantified in maternal blood, and their potency to predict preeclampsia prior to the onset of clinical symptoms has been evaluated. The amount of such markers depends on various conditions, including the source of the marker (fetal/placental and/or maternal), the interaction of this marker with other proteins in maternal blood as well as the stability of the markers during freezing and thawing. Here we describe two of the putative early, first trimester biomarkers, placental protein 13 and placental growth factor. There is still the hope that - even in the absence of any treatment regimen today - such predictive markers will help to speed the development of a cure for preeclampsia.
在过去十年中,已发现多种用于预测先兆子痫的不同生物标志物。这些标志物大多已在母血中检测和定量,并且评估了它们在临床症状出现之前预测先兆子痫的效力。此类标志物的量取决于多种条件,包括标志物的来源(胎儿/胎盘和/或母体)、该标志物与母血中其他蛋白质的相互作用以及标志物在冻融过程中的稳定性。在此,我们描述两种假定的早期妊娠头三个月生物标志物,即胎盘蛋白13和胎盘生长因子。仍有希望的是——即使在当今尚无任何治疗方案的情况下——此类预测性标志物将有助于加速先兆子痫治疗方法的研发。